Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 8:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 1,760 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Formulation #1 Clear all

Conditions: Neoplasms
Interventions: GSK3326595, Pembrolizumab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 6
States / cities: Denver, Colorado • Miami, Florida • New York, New York + 3 more

Conditions: Healthy
Interventions: Benazepril HCl 40 mg Tablets, Lotensin® 40 mg Tablets; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Dry Eye Disease
Interventions: iNexin™ (0.08% aCT1), iNexin™ (0.4% aCT1), iNexin™ (2.0% aCT1), Vehicle (eye drop formulation without aCT1); Drug
Lead sponsor: Xequel Bio, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Healthy Participants
Interventions: Nintedanib, BMS 986278; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Sickle Cell Disease
Interventions: Prasugrel (clinical formulation), Prasugrel (Orally Disintegrating Tablet [ODT]); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Influenza A H3N2, Influenza A H1N1
Interventions: FLU-IGIV, Placebo for FLU-IGIV; Biological · Other
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 42
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 34 more

Conditions: Migraine Headaches
Interventions: ELS-M11, Placebo; Drug
Lead sponsor: Achelios Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Charleston, South Carolina

Conditions: COVID-19
Interventions: Baricitinib, Dexamethasone, Placebo, Remdesivir; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 1,010 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 61
States / cities: Birmingham, Alabama • Fresno, California • La Jolla, California + 50 more

Conditions: Shigella, Diarrhea
Interventions: IVT Shigella-04, Placebo (0.9% saline); Biological
Lead sponsor: Inventprise Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Treatment Resistant Depressive Disorder
Interventions: Esketamine 14 mg, Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 20 Years to 64 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 14
States / cities: Birmingham, Alabama • Garden Grove, California • Hartford, Connecticut + 11 more

Conditions: Influenza Immunization, Healthy Volunteers
Interventions: Quadrivalent Inactivated Influenza High Dose, COVID-19 mRNA Vaccine (nucleoside modified); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 65 Years and older
Enrollment: 306 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 6
States / cities: Glendale, Arizona • San Diego, California • Vista, California + 3 more

Conditions: Advanced Solid Tumors, Lymphoma
Interventions: PX-478; Drug
Lead sponsor: Cascadian Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: Scottsdale, Arizona • Houston, Texas

Conditions: Pyruvate Dehydrogenase Complex Deficiency
Interventions: Dichloroacetate (DCA), Placebo, Genotype; Drug · Other · Genetic
Lead sponsor: Saol Therapeutics Inc; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 10
States / cities: Orange, California • Stanford, California • Washington D.C., District of Columbia + 7 more

Conditions: Healthy
Interventions: LY3471851, Placebo, Levocetirizine; Drug
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Vitiligo
Interventions: Rapamycin, Placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 13 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Healthy Participants
Interventions: Treatment A: BGF MDI HFO, Treatment B: BGF MDI HFA; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, Metformin, DA-1241; Drug
Lead sponsor: Dong-A ST Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Crohn's Disease
Interventions: GSK1605786 ChemoCentryx: formulation A, GSK1605786 GSK: formulation B, GSK1605786 GSK direct-fill: formulation C, GSK1605786 GSK modified-process: formulation D, GSK1605786 GSK tablet: formulation E; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Hyponatremia, Inappropriate ADH Syndrome
Interventions: Urea; Drug
Lead sponsor: Helbert Rondon Berrios, MD, MS; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pulmonary Arterial Hypertension
Interventions: Tadalafil- Tablet or Oral suspension; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 5
States / cities: Aurora, Colorado • Atlanta, Georgia • Indianapolis, Indiana + 2 more

Conditions: Infections, Meningococcal
Interventions: MenABCWY-2Gen low dose vaccine, MenABCWY-2Gen high dose vaccine, Placebo, MenB vaccine, MenACWY vaccine; Combination Product · Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 10 Years to 50 Years
Enrollment: 1,440 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 12
States / cities: Colorado Springs, Colorado • Longmont, Colorado • Doral, Florida + 9 more

Conditions: Osteoarthritis, Fibromyalgia
Interventions: NEM Formulation X, NEM Formulation Y; Dietary Supplement
Lead sponsor: ESM Technologies, LLC; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Jenks, Oklahoma

Conditions: Pain
Interventions: placebo, ibuprofen Formulation 1, ibuprofen Formulation 2; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 16 Years to 40 Years
Enrollment: 211 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Breast Cancer
Interventions: lapatinib ditosylate, paclitaxel albumin-stabilized nanoparticle formulation; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 5
States / cities: Chicago, Illinois • Joliet, Illinois • Olympia Fields, Illinois + 1 more

Search by objective public record fields.

An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma

Benazepril HCl 40 mg Tablets, Fasting

Evaluation of the Safety, Tolerability and Efficacy of iNexin™ for the Treatment of the Signs and Symptoms Associated With Dry Eye Disease

A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Nintedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy Participants

A Relative Bioavailability Study of a Prasugrel Orally Disintegrating Tablet

Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A

Study to Determine the Efficacy and Safety of ELS-M11 in Acute Migraine

Adaptive COVID-19 Treatment Trial 4 (ACTT-4)

First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults

A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine

Phase I Trial of PX-478

Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency:

A Phase I Study of LY3471851 in Healthy Participants

Daily Topical Rapamycin for Vitiligo

A Study to Investigate the Exposure of Budesonide, Glycopyrronium, and Formoterol (BGF) Delivered by Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) Compared to a Hydrofluoroalkane (HFA) Propellant MDI in Healthy Adults

A Study To Evaluate The Safety,Tolerability, PK and PD Of DA-1241 In Healthy Male Subjects

A Study to Assess the Relative Bioavailability of Four New Formulations of GSK1605786 in Healthy Subjects

Urea for Chronic Hyponatremia

A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension

A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults

Efficacy & Safety Study of Natural Eggshell Membrane (NEM) for the Treatment of Joint & Connective Tissue Disorders

Study Comparing the Efficacy of Two Ibuprofen Formulations

Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer